CN101663584A - 未分离的循环癌细胞的Her-2/neu蛋白的检测和治疗 - Google Patents

未分离的循环癌细胞的Her-2/neu蛋白的检测和治疗 Download PDF

Info

Publication number
CN101663584A
CN101663584A CN200880012580A CN200880012580A CN101663584A CN 101663584 A CN101663584 A CN 101663584A CN 200880012580 A CN200880012580 A CN 200880012580A CN 200880012580 A CN200880012580 A CN 200880012580A CN 101663584 A CN101663584 A CN 101663584A
Authority
CN
China
Prior art keywords
neu
immunoassay
cancer cells
cells
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880012580A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·M·劳伦斯
鲁明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WILSDAT BIOLOGICALS Inc
Original Assignee
WILSDAT BIOLOGICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WILSDAT BIOLOGICALS Inc filed Critical WILSDAT BIOLOGICALS Inc
Publication of CN101663584A publication Critical patent/CN101663584A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880012580A 2007-04-19 2008-04-15 未分离的循环癌细胞的Her-2/neu蛋白的检测和治疗 Pending CN101663584A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91283307P 2007-04-19 2007-04-19
US60/912,833 2007-04-19

Publications (1)

Publication Number Publication Date
CN101663584A true CN101663584A (zh) 2010-03-03

Family

ID=39875858

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880012580A Pending CN101663584A (zh) 2007-04-19 2008-04-15 未分离的循环癌细胞的Her-2/neu蛋白的检测和治疗

Country Status (7)

Country Link
US (1) US20100120072A1 (enExample)
EP (1) EP2145188A4 (enExample)
JP (1) JP2010525326A (enExample)
CN (1) CN101663584A (enExample)
CA (1) CA2684265A1 (enExample)
MX (1) MX2009011228A (enExample)
WO (1) WO2008130910A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
JP6245147B2 (ja) * 2014-11-19 2017-12-13 株式会社オートネットワーク技術研究所 モールド部付電線
JP6323317B2 (ja) * 2014-12-09 2018-05-16 株式会社オートネットワーク技術研究所 端子付電線

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451225B1 (en) * 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6448091B1 (en) * 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
NO180658C (no) * 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
AU2365895A (en) * 1994-04-26 1995-11-16 Regents Of The University Of Michigan, The Unitary sandwich enzyme immunoassay cassette, device and method of use
US5744367A (en) * 1994-11-10 1998-04-28 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
CA2223027A1 (en) * 1995-06-07 1996-12-19 Igen, Inc. Electrochemiluminescent enzyme immunoassay
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
US6297062B1 (en) * 1996-03-07 2001-10-02 Bio-Magnetics Ltd. Separation by magnetic particles
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
EP1062515B1 (en) * 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US6969615B2 (en) * 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JP3313107B2 (ja) * 2001-03-22 2002-08-12 バイエル コーポレイション ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
DE10143776A1 (de) * 2001-09-06 2003-04-03 Adnagen Ag Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs
CA2462914A1 (en) * 2001-10-11 2003-04-17 Aviva Biosciences Corporation Methods, compositions, and automated systems for separating rare cells from fluid samples
EP1597353B1 (en) * 2003-02-27 2010-11-24 Veridex, LLC CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
JP4798801B2 (ja) * 2004-10-06 2011-10-19 ウェルスタット バイオロジクス コーポレイション 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
CA2647843A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells
EP2008103B1 (en) * 2006-04-18 2010-07-28 Wellstat Biologics Corporation Detection of circulating endothelial cells
CA2647743A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of steroid receptors on circulating carcinoma cells and treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒

Also Published As

Publication number Publication date
JP2010525326A (ja) 2010-07-22
CA2684265A1 (en) 2008-10-30
EP2145188A1 (en) 2010-01-20
EP2145188A4 (en) 2010-06-30
MX2009011228A (es) 2009-11-02
WO2008130910A1 (en) 2008-10-30
US20100120072A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
CN101663584A (zh) 未分离的循环癌细胞的Her-2/neu蛋白的检测和治疗
JP4798801B2 (ja) 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置
Cao et al. Plasma soluble HLA‐G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer
JP2010525326A5 (enExample)
He et al. HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro
JP5078100B2 (ja) 循環癌細胞におけるステロイド受容体の検出および処置
Wu et al. Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy
KR20220158231A (ko) 무세포 뉴클레오솜 수준을 사용한 분류 방법
Liu et al. PlexinA1 activation induced by β2-AR promotes epithelial-mesenchymal transition through JAK-STAT3 signaling in human gastric cancer cells
Li et al. Retrospective analysis of the efficacy of adjuvant cytokine‐induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery
Wang et al. Chronic Stress exacerbates the immunosuppressive microenvironment and progression of gliomas by reducing secretion of CCL3
JP7255896B2 (ja) シクロホスファミド療法に対する応答者の予測
Ferguson et al. Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance
EP3003371A1 (en) Materials and methods for treatment of liver cancer background of the invention
EP3304086B1 (en) Method for predicting responsiveness to a combination therapy with lenvatinib and everolimus
Theodoraki et al. Plasma‑derived CD16 exosomes and peripheral blood monocytes as correlating biomarkers in head and neck cancer
JP2020521973A (ja) 腎機能を診断またはモニターする方法、または腎機能障害を診断する方法
TW201930881A (zh) 大腸直腸腺瘤之檢測及治療方法
Yang et al. VEGFD/VEGFR2 axis induces the dedifferentiation of high endothelial venules and impairs lymphocyte homing
Ulukaya et al. sFas levels increase in response to cisplatin‐based chemotherapy in lung cancer patients
JP7012363B2 (ja) がん患者におけるｆｓｔｌ１阻害剤による治療効果を予測するためのバイオマーカー
EP4321176A1 (en) Pulmonary arterial hypertension patient selection method and biomarker
Wu et al. Chronic stress-induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis
Artuyants et al. The tumour-derived extracellular vesicle proteome varies by endometrial cancer histology and is confounded by an obesogenic environment
KR101757731B1 (ko) 레지스틴 단백질 함량을 측정하는 물질을 포함하는 어혈 진단용 조성물, 키트 및 이를 이용하는 진단방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100303